Search Submit
Close

Cancer Nature (CN)

DOI:10.24983/scitemed.cn
Online ISSN: Coming soon

Cancer Nature (CN)

Cancer Nature (CN) is a peer-reviewed open access scientific journal published by SciTeMed Publishing Group. 

Cancer Nature provides an integrated view of modern oncology across all disciplines.The journal covers all aspects of cancer research, including the pathophysiology, prevention, diagnosis and treatment of cancers. Cancer Nature welcomes submissions concerning molecular and cellular biology, genetics, epidemiology, and clinical trials.

Cancer Nature provides readers with critically peer-reviewed, carefully selected and up-to-date publications. All the manuscripts submitted to CN will be subjected to peer-review by the Editors of the respective specialty section. The review process will be conducted by the handling editor alone or by collaborating with the outside experts. The decision will be finalized by the editor considering and analyzing the minimum of two independent reviewer’s comment. Authors may submit manuscripts and track the current status of their manuscript through the submission tracking system. Reviewers can download manuscripts and submit their comment to the editor through the same system, and editors can manage or monitor the whole submission/review/revise/publish process.

Coming Soon...
Coming Soon...

    Coming Soon...

Editorial Board

  • Luis Rodrigo, MD, PhD

    Professor Emeritus, Department of Medicine
    University of Oviedo
    Spain (España)
    Prof. Luis Rodrigo the Emeritus Professor of Medicine at the University of Oviedo (Spain). He has been the Chief of Gastroenterology Service at the HUCA Hospital in Oviedo, for more than 40 years. He obtained his PhD at 1975 and has developed a long teaching and research career. Prof. Rodrigo is a distinguished researcher, he has more than 500 scientific publications. He has participated as an main investigator in a total of 45 clinical trials. In addition, he has authored more than 30 book chapters of several subjects and has been the Editor of 10 books in his speciality. One of Prof. Luis Rodrigo’s main areas of interest is related to the evolution of the treatment of Chronic Viral Hepatitis mainly caused by HBV and HCV alone and also in HIV coinfected patients and all the changes occurred in the last 3-4 decades. Another of his research area is about Celiac disease, their diagnosis and the Associated Diseases (mainly neurological, rheumatological and dermatological) with this complicated and diverse presentation of this gluten intolerance. Prof. Luis Rodrigo’s research interests also include Hepatocellular Carcinoma, and the prevention, diagnosis and treatment of colon cancer and its different variants and stages of evolution.
  • Kiastoutis Planoutis, PhD

    Department of Hematology/Oncology
    Icahn School of Medicine
    United States

    Dr. Planoutis is Assistant Professor of Icahn School of Medicine at Mount Sinai in New York, USA. He is also holding position at American Association for Cancer Research. His research interests include Wnt signaling in cancer, colorectal cancer stem cells, cancer therapy resistance, and tumor microenvironment. Dr. Planoutis serves as article reviewer in highly ranked medical journals. He has an extensive list of recent publications, including book chapters, reviews, SCI original papers, and presentations in international medical congresses.

  • Michael Liebman, PhD

    Adjunct Professor, Department of Pharmacology and Physiology
    Drexel College of Medicine
    United States

    Professor Michael N. Liebman received his PhD in Theoretical Chemistry and Protein Crystallography at the University of Wisconsin, Madison, WI. He currently serves as the Managing Director of IPQ Analytics and Strategic Medicine. Professor Liebman has vast experience of teaching and research. He is an Adjunct Professor of Pharmacology and Physiology at Drexel College of Medicine and Adjunct Professor of Drug Discovery, First Hospital of Wenzhou Medical University and also Fudan University. He was an Associate Professor of Pharmacology and of Physiology/Biophysics at Icahn School of Medicine at Mount Sinai, in New York City. Professor Liebman serves on 14 scientific advisory boards and the Board of Directors of the Nathaniel Adamczyk Foundation in Pediatric ARDS and Innovene Pharmaceuticals.Professor Liebman is Chair of the Informatics Program and also Chair of Translational Medicine and Therapeutics for the PhRMA Foundation and a member of their Scientific Advisory Board. He is on the Advisory Board of the International Society for Translational Medicine and on the Editorial Board for the Journal of Translational Medicine, for Clinical and Translational Medicine and for Molecular Medicine and Therapeutics, for Clinico-Economics and Outcomes Research and Biomedicine Hub, and the International Park for Translational Biomedicine. Professor Liebman is a member of the IUPAC Division on Human Health’s Medicinal Chemistry subcommittee. He has served on the External Advisory Board for the INBRE (NIH) program for the state of Delaware since 2000. He is an Invited Professor at the Shanghai Center for Bioinformatics Technology and of the Chinese Academy of Sciences. Professor Liebman’s research focuses on computational models of disease progression that stress risk detection, disease processes and clinical pathway modeling, and disease stratification from the clinical perspective. He utilizes systems-based approaches and design thinking to represent and analyze risk/benefit analysis in pharmaceutical development and healthcare.

  • Chin-Lung Kuo, MD, PhD

    Chief, Department of Otolaryngology-Head and Neck Surgery
    Taoyuan Armed Forces General Hospital
    Taiwan (台灣)

    Dr. Chin-Lung Kuo is the Director of the Department of Otolaryngology, Taoyuan Armed Forces General Hospital, Taiwan, ROC. Dr. Kuo received his medical degree from the National Defense Medical Center and earned his PhD degree at the Institute of Brain Science, National Yang-Ming University, Taiwan, ROC. He completed his otolaryngology residency, chief residency, and fellowship training at the Department of Otolaryngology-Head and Neck Surgery, Taipei Veterans General Hospital, Taiwan, ROC. Dr. Kuo continues to make contributions to the scientific community. His primary field of study is otology, and his research is focused on middle ear surgery and hearing loss. Dr. Kuo has been invited to speak at international conferences and institutes. Dr. Kuo has been the first or corresponding author on more than 50 published articles in the last 5 years, including SCI original papers, review articles, as well as book chapters. In 2012, his research paper was chosen as the cover story of the journal Audiology and Neurotology. In addition, Dr. Kuo received the Outstanding Paper Award from the Laser Medicine Education and Research Foundation in 2013, and was awarded the 2015 Hayashi SPIO (Society for Promotion of International Otorhinolaryngology) Scholarship in Japan. Dr. Kuo believes that increased availability of research data can benefit both medical research and science education. For further details regarding his research, please use the following link to access his blog.

  • George Griffing, MD

    Professor Emeritus, Department of Medicine
    Saint Louis University
    United States
    Dr. George Griffing is a retired Professor of Medicine at St. Louis University in St. Louis, Missouri. Dr. Griffing’s specialty is Internal Medicine and his subspecialty is Endocrinology, Diabetes and Metabolism. He has Board Certification in Internal Medicine and Endocrinology, Diabetes and Metabolism. In 1992 he became Professor of Medicine, Chief of Endocrinology, Diabetes and Metabolism, and Director of the Cosmopolitan International Diabetes Center at the University of Missouri-Columbia until 1999. From 1999 until 2006 he served as Director of General Internal Medicine at Saint Louis University. He is currently Professor of Medicine and a member of the Endocrinology faculty at Saint Louis University. Dr. Griffing’s research interests include inhaled insulin, nasal insulin, and novel diabetes treatments. He is a prolific author, with over 200 articles and abstracts published to date. Dr. Griffing is currently the Editor-in-Chief of eMedicine Internal Medicine and is an ad hoc editorial consultant on several publications, including the New England Journal of Medicine and Diabetic Medicine. He is a member of numerous professional societies including the American Association of Clinical Endocrinologists and the American Diabetes Association. Dr. Griffing has nearly 40 years of diabetes experience including treating, teaching and researching the topic.
  • Nicole D Riddle, MD, FCAP

    Assistant Professor, Department of Pathology and Laboratory Medicine
    University of South Florida College of Medicine
    United States

    Dr. Riddle is a Staff Pathologist at Tampa General Hospital for Ruffolo, Hooper, and Associates as well as Assistant Professor for the University of South Florida College of Medicine in the Department of Pathology and Laboratory Medicine where she serves as Residency Research Liaison and Site Director. Organized medicine is something she enjoys and is very active holding positions with the American Medical Association, the College of American Pathologists, the Digital Pathology Association, and the United States and Canadian Academy of Pathology. Her research Interests include the pathology of bone and soft tissue, neuro, and GI tract. Dr. Riddle is an active researcher with extensive publications, she has authored more than 30 published articles including SCI original papers, review articles, as well as book chapters. She is in the editorial board of international peer-reviewed journals. Dr. Riddle has participated with numerous presentations in international medical congresses and served as grant and article reviewers in highly ranked medical journals. 

  • Jason Cheng, MD, PhD

    Hematopathology Section, Department of Pathology
    University of Chicago
    United States

    Jason Cheng, MD, PhD, serves as an assistant professor and an attending physician in the Section of Hematopathology, University of Chicago. Dr. Cheng obtained his medical degrees Peking (Beijing) Medical University and Kunming Medical University in China. He received his PhD under the guidance of Dr. Rudy L. Juliano, in the Department of Pharmacology at the University of North Carolina-Chapel Hill (UNC-CH). He pursued his post-doctoral training in yeast genetics and gene regulation in the laboratory of Dr. Mark Ptashne, at Memorial Sloan Kettering Cancer Center in New York. Dr. Cheng completed his residency in anatomic and clinical Pathology at University of Chicago and his fellowship training in Hematopathology under the guidance of Dr. James W. Vardiman at the University of Chicago. During his PhD. at UNC-CH, he made an invention of a novel technology (US patent no 5,869,250, 1999) for identity sequence-specific DNA-binding peptides for constructing artificial transcription factors and gene regulation. During his residency and clinical fellow training, he first identified the loss of protein expression of INI1/hSNF5/BAF47/SMARCB1 as a hallmark for diagnosis of renal medullary carcinoma (Modern Pathology, 2008). He also won the 2008 Pathologist-in-Training Award from the Society for Hematopathology and the 2008  Paul E. Strandjord Young Investigator Award from the Academy of Clinical Physicians and Scientists for conducting the first genome-wide epigenetic profiling of DNA and H3K27 trimethylation in clinical MDS specimens. He received the Cancer Research Foundation Young Investigator Award in 2014. He published multiple papers in peer-reviewed, high-impact factor journals including Leukemia, PNAS, Immunity and Molecular Cell.

Assistant Editors

    Coming Soon...

Early View

  • Cellular Proliferative Domains: Barriers to Migration

    An important aspect of the analysis of the proliferation of cell populations as composed of a set of intercommunicating logistic domains is the nature of the barriers between adjacent domains and the regulation of cellular migration between them. The nature of these inter-domain boundaries is discussed in relation to the central role of L-type calcium channels in the control of cell motility and it is proposed that domain boundaries are determined by proteoglycans which act as calcium chelators and hence regulate the local extracellular Ca++ concentration. The selective migratory advantage gained by overexpression of calcium channels is briefly alluded to.

    Cancer Nature. 2018;1(1):1
    DOI: 10.24983/scitemed.cn.2018.00079
    Article Type: Perspective, Opinion, or Commentary

Current Issue

Archive